Panelists 4325

July 1, 2007

4 Min Read
MDDI logo in a gray background | MDDI

FINANCE

Panel Discussion: Venture Capital and Angel Investors





Frederick J. Dotzler is a cofounder and managing director at De Novo Ventures (Palo Alto, CA), a healthcare venture capital firm. He is a member of the board of directors of Bayhill Therapeutics, Cartilix, Point Biomedical, Senorx, Talima, and Vitreo Retinal Technologies. At De Novo, Dotzler has also invested in Favrille, Oncomed, Renovis, and Microvention, the last of which was purchased by Terumo in 2006.

Dotzler was previously managing general partner of Medicus Venture Partners, which he founded in 1989. Prior to Medicus, Dotzler was a general partner with Crosspoint Venture Partners for five years, where he invested in medical and technology companies. Prior to joining Crosspoint, he served in executive positions in finance, marketing, sales, manufacturing, and business development for companies selling pharmaceuticals (Searle), medical instruments (Merrimack), biotechnology research tools (Millipore), and computers (IBM).

Dotzler earned an MBA from the University of Chicago, a master's equivalent in economics from the University of Louvain, Belgium, and a BS in engineering from Iowa State University, where he received a professional achievement citation in engineering in 2000. He is a member of the advisory board of the Journal of Private Equity and a member of the MX magazine editorial advisory board council on finance.

Robert S. Behl, founder, president, and CEO of Percutaneous Systems Inc. (Mountain View, CA), is a serial entrepreneur in the medical device marketplace. After successful line-management experience in R&D, marketing, and business development for three major medical device companies, Behl founded and served as general manager for Sybron's clinical technology–Bovie division (purchased by Maxxim), accomplished a major turnaround as CEO of Menlo Care (now part of Johnson & Johnson), and founded and served as first CEO at both InnerDyne (now part of U.S. Surgical–Covidien) and RadioTherapeutics (now part of Boston Scientific).

Behl serves on the board of Guided Delivery Systems, a pioneering cardiology company, and is active in Life Science Angels. He holds a BS in mechanical engineering, an MS in biomedical engineering, and an MBA in economics and finance from the University of Rochester's William E. Simon Graduate School of Management.

Mike Carusi is a general partner at Advanced Technology Ventures (ATV; Palo Alto, CA). He joined ATV in 1998, and focuses on investments in the life sciences and medical device sectors. His representative investments include Emphasys Medical, EndoGastric Solutions, GI Dynamics, GluMetrics, NeuroVista, Plexxikon, TranS1, Xtent, and MicroVention (acquired by Terumo).

Carusi has more than a decade of operational and management consulting experience. Prior to joining ATV, he served as the director of business development for Inhale Therapeutic Systems (now Nektar Therapeutics), a venture-backed pulmonary-drug delivery company that went public in 1994. At Inhale, he led partnering activities with a number of well-established pharmaceutical and biotechnology companies in the United States, Europe, and Japan.

Carusi was also a principal at the Wilkerson Group, a strategic ATV partner and leading management consulting firm focused exclusively on healthcare. At the Wilkerson Group, he helped establish the firm's offices in London and San Francisco.

Carusi holds an MBA from the Amos Tuck School of Business Administration at Dartmouth College and a BS from Lehigh University.

J. Casey McGlynn is a partner at Wilson Sonsini Goodrich & Rosati (Palo Alto, CA), chairman of the firm's life sciences group, and a member of the firm's policy committee. Since joining the firm in 1978, he also has been a member of the firm's executive, nominating, and compensation committees. McGlynn's practice focuses on the organization, funding, and corporate representation of companies in the information technology, life sciences, and telecommunications industries.

McGlynn is a nationally recognized leader in the representation of start-up and growth technology companies. He assists his clients in meeting their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, corporate partners, and investment bankers. He has experience representing dozens of companies that have made successful initial public offerings and secondary offerings.

McGlynn received his BA and JD degrees with highest honors from Santa Clara University. He is a contributor to magazines and newsletters focused on angel and venture investing, and frequently speaks on issues related to the organization and funding of new ventures.

Copyright ©2007 MX

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like